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Control of diseasesinﬂicted by protozoanparasitessuch asLeishmania, Trypanosoma,andPlasmodium,w h i c hp o s eas e r i o u st h r e a t
to human health worldwide, depends on a rather small number of antiparasite drugs, of which many are toxic and/or ineﬃcient.
Moreover, the increasing occurrence of drug-resistant parasites emphasizes the need for new and eﬀective antiprotozoan drugs.
In the current study, we describe a synthetic peptide, WRWYCRCK, with inhibitory eﬀect on the essential enzyme topoisomerase
I from the malaria-causing parasite Plasmodium falciparum. The peptide inhibits speciﬁcally the transition from noncovalent
to covalent DNA binding of P. falciparum topoisomerase I, while it does not aﬀect the ligation step of catalysis. A mechanistic
explanation for this inhibition is provided by molecular docking analyses. Taken together the presented results suggest that
synthetic peptides may represent a new class of potential antiprotozoan drugs.
1.Introduction
Protozoan parasites, such as Leishmania, Trypanosoma,a n d
Plasmodium species are the cause of a large array of diseases
hampering the lives of people all over the world [1]. Control
of such diseases depends on a rather small number of
prophylactic or therapeutic antiparasite drugs, many of
which are highly toxic and/or ineﬃcient [2–5]. In addition,
an increasing number of parasites developresistance towards
several of the frontline drugs [6–9]. This has created an
urgent need for novel compounds to prevent and cure
diseases caused by protozoan parasites. Species-speciﬁc
inhibition of parasitic enzymes has been suggested as one
promising approach in the development of new therapeutics
[10]. One family of enzymes that have attracted considerable
interest as potential targets for antiparasitic therapeutics are
theDNAtopoisomerases(Topos)[1,11]ofwhichthehuman
counterparts are well-known targets in anticancer treatment
[12].
DNA Topos are ubiquitousenzymes needed to overcome
the topological stress arising in DNA during replication,
transcription, recombination, and repair [13]. This is
achieved by the enzymes introducing transient breaks in the
DNA in a reaction that restores the energy of the broken
phosphodiester bond in a covalent phosphotyrosyl cleavage
intermediate. Based on their mechanism of action Topos are
divided into two main classes [13, 14]. The type I Topos are
with few exceptions monomers and relax DNA by breaking
only one strand of the double helix, while type II Topos
are mainly homodimers or heterotetramers and break both
strands of the DNA simultaneously. Type I Topos are further
classiﬁed into two structurally unrelated families denoted
the type IA and type IB Topos, deﬁned by the polarity of
their strand cleavage. The type IA Topos are prevalent in
prokaryotic species and create a 5 -phoshotyrosyl linkage
and a free 3 -OH DNA end during cleavage. Type IB Topos
are mainly found in eukaryotic species and generate a 3 -
phosphotyrosyl linkage and a free 5 -OH DNA end during2 Molecular Biology International
cleavage. The class of type II Topos are subdivided into the
type IIA and type IIB families, of which all members are
structurally related and characterized by the formation of a
5 -phoshotyrosyl linkage and a free 3 -OH DNA end during
cleavage. The type IIA Topos are found both in eukaryotic
andprokaryoticspecies. Typicallytheeukaryoticmembersof
this group are homo-dimers while the prokaryotic enzymes
are heterotetramers [14]. The type IIB group encompasses
TopoVI of extreme thermophilic archaebacteria [15].
Besides theirimportant biologicalfunctions, DNATopos
from the various groups are well-known targets of both
antibacterial and anticancer therapeutic agents. Hence, bac-
terial type IIA Topos, such as DNA gyrase and TopoIV,
are targets of clinically important antibiotics active against
a wide spectrum of bacterial pathogens [16, 17]. Human
type IB and IIA Topos are targets of several anticancer
compounds, exempliﬁed by camptothecin and etoposide,
respectively, of which synthetic derivatives are routinely used
in systemic treatment of diﬀerent cancer types [12, 18]. Of
relevance for the treatment of protozoan-caused infectious
diseases, structural and/or subtle mechanistic diﬀerences
between protozoan and host Topos can be exploited for the
rational design of novel therapeutic compounds. Indeed,
the unusual heterodimeric TopoIB of kinetoplastid parasites,
such as Leishmania donovani gives hope for the development
of drugs targeting parasite TopoIB without interfering with
the function of the monomeric TopoIB in the human host
[11, 19, 20]. As another example, the apicomplexan parasite
Plasmodium falciparum contains apicoplast DNA, which
requires bacterial-type DNA gyrases (type IIA Topo) for
replication, thus providing a unique drug target absent in
the host [21, 22]. In addition, the high expression rate of
TopoIB and TopoIIA in rapidly growing parasites, compared
to the expression levels of these enzymes in the host, may
beexploitedforthedevelopmentofTopo-targetingprotocols
that speciﬁcally kill the parasites.
Synthetic peptides have been prophesied to be the ideal
inhibitors of enzyme activity either alone or in combination
with small-molecule drugs [10, 23]. However, high synthesis
costs and great challenges regarding delivery, intracellular
targeting and clearance half-life of peptides have until
recently hampered the interest of most pharmaceutical
companies in developing peptide-based drugs. New eﬃcient
synthesis strategies and low monomer prices have led to a
renewed interest in therapeutic peptides. Indeed, compared
to small-molecule drugs, which are currently dominating
the pharmaceutical market, peptide-based therapeutics oﬀer
several advantages, such as high speciﬁcity, lower accumula-
tion in tissues, lower toxicity, and biological diversity [24–
27].
The potential for synthetic peptides as eﬃcient species-
speciﬁc inhibitors even of discrete steps of Topo catalysis is
highlighted in several studies by Nagaraja and co-workers
describing the identiﬁcation and characterization of species-
speciﬁc antibodies with inhibitory activities against partic-
ular steps of Mycobacteria DNA gyrase or TopoI catalysis
[28–30]. Peptides with similar inhibitory activities and
potential in future antituberculosis treatment [29] are likely
to be derived from such antibodies [31–34]. Relevant for
the potential development of peptide-based drugs targeting
eukaryotic Topos, almost a decade ago, Segall and co-
workers identiﬁed a series of hexapeptides inhibiting various
catalytic steps of the tyrosine recombinases (bacteriophage
λ-Int and Cre) [35, 36]. Tyrosine recombinases share so
important structural and mechanistic features with the type
IB Topos that they can be considered a subbranch of the
type IB Topo family [37, 38]. It was therefore not surprising,
that several of the hexapeptides selected on basis of λ-Int
inhibition also inhibited DNA relaxation by the type IB
Topo of Vaccinia virus(vvTopoI),althoughlesspotently[39].
A rescreening of the peptide combinatorial library (used
for selection of the above-mentioned peptides) speciﬁcally
against vvTopoI resulted in the identiﬁcation of three new
peptides, WYCRCK, KCCRCK, and WRWYCRCK with high
activity against this enzyme. Of these, WRWYCRCK was
the most potent inhibitor of the type IB Topos tested. This
peptide inhibited vvTopoI with an IC50 value of 0.1–0.25μM
and λ-Int with an IC50 value of 0.015μM, while the struc-
turally unrelated type IA Topo, E. coli TopoI was inhibited
only to a limited extent (IC50 value of 5.5μM) [40]. Using
these peptides as a starting point, it may in longer terms be
possible to develop peptide-based TopoI targeting inhibitors
with therapeutic activity against protozoan pathogens.
As an initial investigation of this possibility, we address,
in the present study, the eﬀect of the peptides WYCRCK,
KCCRCK, and WRWYCRCK on the activity of the recently
cloned and puriﬁed recombinant TopoI (pfTopoI) from the
malaria-causing parasite Plasmodium falciparum.W eﬁ n d
that WRWYCRCK inhibits DNA relaxation and cleavage by
pfTopoI whereas neither WYCRCK nor KCCRCK have any
eﬀect on pfTopoI activity. Molecular docking of the three
peptides in the noncovalent pfTopoI-DNA complex shows
WRWYCRCK to be located in the minor groove of the DNA
in proximity of the enzyme active site, while WYCRCK and
K C C R C Ka r ep o s i t i o n e df a rf r o mt h ee n z y m ea c t i v es i t e .
2.Methods
2.1. Expression and Puriﬁcation of pfTopoI. The plasmid,
pPFT100 (the cloning of pfTopoI is to be published else-
where), containing the pfTopoI gene (PlasmoDB accession
number PFE0520c) [41] (codon optimized for expression
in S. cerevisiae (GENEART, Germany)), was transformed
into the yeast S. cerevisiae top1Δ strain RS190 (a kind gift
from R. Sternglanz, State University of New York, Stony
Brook, NY, USA) according to standard procedures, and
pfTopoI enzyme was expressed and puriﬁed as previously
described for human topoisomerase I (hTopoI) [42]. hTopoI
was expressed and puriﬁed as previously described [42].
2.2. Unit Deﬁnition. 1U is the amount of enzyme needed to
fully relax 200fmol of negatively supercoiled pBR322 plas-
mid DNA at 37◦C in 30min in 10mM Tris (pH 7.5), 1mM
EDTA, 150mM NaCl, 5mM MgCl2 and 5mM CaCl2.Molecular Biology International 3
2.3. Synthetic Peptides. WYCRCK, KCCRCK, and
WRWYCRCK were purchased from GenScript USA Inc.,
USA. The lyophilized peptides were dissolved in H2O.
2.4. Relaxation Assays. DNA relaxation reactions included
1U pfTopoI in the absence or presence of peptide
(WYCRCK, KCCRCK, or WRWYCRCK) at the following
concentrations: 1.3μM, 2.5μM, 5μM, 7.5μM, 12.5μM,
25μM, or 50μM and 200fmol negatively supercoiled
pBR322 plasmid in 20μL of 10mM Tris (pH 7.5), 1mM
EDTA, 150mM NaCl, 5mM MgCl2 and 5mM CaCl2.T h e
plasmid was preincubated with the peptide for 5min at
37◦C prior to addition of enzyme. Reactions were incubated
at 37◦C for 30min before being stopped by addition of
0.2% (w/v) SDS and proteolytically digested with 0.5μg/mL
proteinase K for another 30min at 37◦C. Samples were
subjected to gel electrophoresis on 1% agarose gels in TBE
buﬀer, and DNA bands were stained with ethidium bromide
and visualized by illumination with UV light.
2.5.SyntheticDNASubstrates. Oligonucleotidesforassembly
of DNA suicide cleavage substrates and DNA ligation sub-
strates were purchased from DNATechnology, Denmark and
puriﬁed by denaturing polyacrylamide gel electrophoresis.
The sequences of the substrates are as follows: OL19: 5 -
GCC TGC AGG TCG ACT CTA GAG GAT CTA AAA
GAC TTA GA-3 , OL27: 5 -AAA AAT TTT TCT AAG TCT
TTT AGA TCC TCT AGA GTC GAC CTG CAG GC-3 ,
and OL36: 5 -AGA AAA ATT TTT-3 . The oligonucleotide
representing the scissile strand (OL19) was 5 -radiolabeled
by T4 polynucleotide kinase (New England Biolabs, USA)
using [γ-32P] ATP as the phosphoryl donor. To prevent
ligation of the 5 -OH from the bottom strand (OL27),
these ends were 5 -phosphorylated with unlabeled ATP. The
oligonucleotides were annealed pairwise with a 2-fold molar
excess of the bottom strand over scissile strand as previously
described [43].
2.6. Cleavage/Ligation Assays. The cleavage reactions were
carriedoutin20μL reactionvolumesbyincubating20nMof
the duplex OL19/OL27 with 500fmol of pfTopoI or hTopoI
enzyme at 37◦C, in 20mM Tris (pH 7.5), 10mM MgCl2,a n d
10mM CaCl2. The DNA substrate was preincubated with
peptide WRWYCRCK at concentrations varying from 0 to
75μMfor5minat37 ◦Cpriortoadditionofenzyme.After30
minutes of incubation, the reactions were stopped with 0.1%
(w/v)SDS.Fortheligationreactions, 20nM OL19/OL27was
incubated with 500fmol of pfTopoI for 30min at 37◦Ci n
10mM Tris (pH 7.5), and 5mM MgCl2, 5mM CaCl2.A f t e r
preincubation of the cleavage samples with the peptide at
concentrations varying from 0 to 12.5μMf o r5m i na t3 7 ◦C,
ligation was initiated by the addition of a 200-fold molar
excess of oligonucleotide OL36 over the duplex OL19/OL27.
Samples were incubated at 37◦C for 60min, and reactions
were stopped with 0.1% (w/v) SDS. Cleavage and ligation
sampleswereprecipitatedwithethanol,resuspendedin10μL
of 1mg/mL trypsin, and incubated at 37◦Cf o r3 0 m i n .
Reaction products were analyzed by gel electrophoresis on
12% denaturing polyacrylamide gels, and radioactive bands
were visualized by Phosphorimaging.
2.7. Quantiﬁcation. Densitometric quantiﬁcation of gel
bands was performed using Quantity One v4.6.3 software
(Bio-Rad, USA). The relative cleavage was calculated by the
following equation: relative cleavage = (IC − BI)/(IC − BI
+I S− BI), where IC denotes the intensity of the band(s)
representing the cleavageproduct(s),IS denotesthe intensity
of the band representing the substrate, and BI denotes the
background intensity.
2.8. Restriction Digestion of Plasmid in the Presence of Peptide.
Restrictiondigestswereperformedin20μLreactionvolumes
byincubating3μgpUC19plasmidwithEcoRIorPvuII(both
from New England Biolabs) in the reaction buﬀers provided
by the manufacturer in the absence or presence of peptide
WRWYCRCK (12.5μM, 25μM, or 50μM). The plasmid was
preincubated with the peptide for 5min at 37◦Cp r i o rt o
addition of enzyme. For both restriction endonucleases, the
lowest amount of enzyme, able to fully digest the plasmid
within the timeframe of the experiment, was used. Reactions
were incubated at 37◦C for 30min before being stopped by
addition of0.2% (w/v) SDSand proteolyticallydigested with
0.5μg/mL proteinase K for another 30min at 37◦C. Samples
were subjected to gel electrophoresis on 1% agarose gels in
TBE buﬀer, and DNA bands were stained with ethidium
bromide and visualized by illumination with UV light.
2.9. Docking Experiment. The three-dimensional structure
forresiduesPro140-Phe839ofpfTopoIwasobtainedthrough
homology modeling using the SwissModel server [44]a n d
the crystal structure of hTopoI (1K4T and 1A36 PDBs)
as a template [45, 46]. The alignment was performed
with the TCOFFEE server [47], using the sequences having
the SwissProt code Q26024 and P11387 for the pfTopoI
and hTopoI protein, respectively. The 22-base-pair DNA
present in the noncovalent hTopo1-DNA complex crystal
structure 1K4S [46] was ﬁtted into the putative pfTopoI
active site in the 3D protein model to obtain the pfTopoI-
DNA noncovalent complex that was used for the docking
experiment. The bases are numbered from 1 to 22 starting
from the 5  end of the scissile strand and from 23 to 44
starting from the 5  end of the intact strand. The structure of
the octapeptide WRWYCRCK and of the two hexapeptides
WYCRCK and KCCRCK was designed with the Sybyl v.
6.0 program (TRIPOS, http://www.tripos.com/)c r e a t i n ga
disulphide bond between the two Cys3 and Cys5 cysteines
in all the peptides (this was done since the experimental
data conﬁrmed that disulﬁde bridging was necessary for the
inhibitoryeﬀectofthepeptide).Thestructureofthepeptides
was minimized in vacuum using the Powell algorithm [48]
implemented in the Sybyl program and then simulated in
a rectangular box ﬁlled with water molecules using the
Gromacs 4.0 Package [49] for 2ns in order to regularize
the structure. 250 docking runs were performed using the
Autodock 4.2 program [50] using the Lamarckian genetic
algorithm [51]. The structures of the ligands (WRWYCRCK,4 Molecular Biology International
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Figure 1: Eﬀect of peptides on pfTopoI-mediated DNA relaxation. The eﬀect of peptides on relaxation was assayed by incubating 200fmol
supercoiled plasmidwith enzymeand peptide WRWYCRCK, KCCRCK, orWYCRCK at thefollowingconcentrations:1.3μM,2.5μM,5μM,
7.5μM, 12.5μM, 25μM, or 50μM. (a) Representative gel picture showing the relaxation activity of pfTopoI in the presence of increasing
concentrations of peptide WRWYCRCK. (b) Representative gel picture showing the relaxation activity of pfTopoI in the presence of
increasing concentrations of peptide KCCRCK. (c) Representative gel picture showing the relaxation activity of pfTopoI in the presence
of increasing concentrations ofpeptide WYCRCK. C: negative control lane without any enzyme added; 0: positive control lane with pfTopoI
but no peptide added; SC: supercoiled plasmid; Rn: relaxed topoisomers; Cat: supercoiled catenated plasmid.
WYCRCK, or KCCRCK) and the receptor (pfTopoI-DNA
complex) were ﬁrst prepared using the AutodockTools v.
1.5.2 suite [50], building a cubic box able to contain the
cap and cat domains of the protein and the DNA bases. The
contacts between the ligand and the receptor were identiﬁed
using a cutoﬀ of 3.5 ˚ A applying a modiﬁed version of the
g mindist tool present in the Gromacs 3.3.3 package for
Molecular Dynamics analysis [52] .T h ei m a g e sw e r ec r e a t e d
with the program VMD [53].
3.Results
3.1. Inhibitory Potency of Peptides WYCRCK, KCCRCK, and
WRWYCRCK in Relaxation by pfTopoI. The inhibitory
potency of the peptides WYCRCK, KCCRCK, and
WRWYCRCK on pfTopoI activity was investigated in a
standard plasmid relaxation assay. The assay was performed
with the minimum amount of pfTopoI that suﬃced to
fully relax the plasmid DNA (i.e., convert fast-mobility
supercoiled plasmid to slow-mobility relaxed plasmid
forms) in the absence of added peptide within the timeframe
(30min) used in the experiment (data not shown). As
evident from Figure 1, the peptide WRWYCRCK inhibited
pfTopoI relaxation activity in a dose-dependent manner,
with an IC50 of 2.5–5μM. The peptides WYCRCK, KCCRCK
had no eﬀect on the relaxation activity of pfTopoI, even
at concentrations up to 50μM. Moreover, consistent with
previous reports of inhibition of vvTopoI by WRWYCRCK,Molecular Biology International 5
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Figure 2: Eﬀect of peptide WRWYCRCK on pfTopoI-mediated DNA cleavage. (a) Schematic depiction of the cleavage and religation
reactions. The substrate (OL19/OL27) used for assaying cleavage allows covalent attachment of the enzyme to the 3  end of the 5 -
radiolabeled scissilestrand (OL19) by cleaving oﬀ a trinucleotide. Ligation is prevented by diﬀusion of the trinucleotide. To initiate ligation,
the ligator strand (OL36) is added to covalent cleavage complexes generated by incubating pfTopoI with radiolabeled OL19/OL27. (b) Gel
picture showing the cleavage products obtained by incubating 5 -radiolabeled OL19/OL27 with pfTopoI (lane 1) or hTopoI (lane 2). (c)
Graphical depiction of the cleavage activity of pfTopI plotted as a function of peptide WRWYCRCK concentration. The cleavage activity
was calculated as described in Section 2. (d) Representative gel picture showing the ligation activity of pfTopoI in the presence of peptide
WRWYCRCK at the following concentrations: 1.3μM, 2.5μM, 5μM, 7.5μM, or 12.5μM. T: topoisomerase I; asterisk: 5 -radiolabel with
[γ-32P];ﬁlled circle: 5 -cold phosphorylation;S: substrate; Cl1: cleavageproduct resulting from cleavage at the black arrow in the schematic
depiction; Cl2: cleavageproduct resulting from cleavage two nucleotides upstream ofthe black arrow in the schematic depiction; C: negative
control lanes without any enzyme added; Cl: cleavagecontrol lane withoutligator strand added; 0: positive control lanewith pfTopoI but no
peptide added.6 Molecular Biology International
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Figure 3: Eﬀect of peptide WRWYCRCK on restriction digestion
by restriction endonucleases. Representative gel picture showing
the result of incubating pUC19 plasmid with EcoRI (lanes 4–7) or
PvuII (lanes 8–11) in the presence of peptide WRWYCRCK at the
following concentration: 12.5μM, 25μM, or 50μM. The sizes, kbp,
of the DNA marker (lane 1, labeled M) are shown to the left of the
gel picture. 0: control lanes with no peptide added; +: control lane
with50μM peptide added; asterisks indicate the gel electrophoretic
mobility of the digested plasmid, for EcoRI, 2.7kbp, and for PvuII,
0.3kbp and 2.4kbp.
the peptide only retained its inhibitory eﬀect in the absence
of DTT (data not shown), suggesting that the active form of
the peptide involves disulﬁde bridging.
3.2. Inhibitory Potency of Peptide WRWYCRCK in Cleav-
age/Ligation by pfTopoI. DNA relaxation by type IB Topos
involves two discrete transesteriﬁcation reactions that is, a
cleavagereaction, in which the active site tyrosine attacks the
phosphodiester bond of the DNA backbone to generate a 3 -
phosphotyrosyl cleavage intermediate and a free 5 -OH end,
and a ligation reaction in which the 5 -OH acts as a nucle-
ophile on the phosphotyrosyl bond to restore intact DNA.
It was previously demonstrated that the inhibitory eﬀect
of the peptides WYCRCK, KCCRCK, and WRWYCRCK on
DNA relaxation by vvTopoI and λ-Int could be ascribed to
a speciﬁc inhibition of the cleavage and not the ligation
step of catalysis [39, 40]. To address which steps of pfTopoI
catalysis are aﬀected by peptide WRWYCRCK, that inhibited
relaxationbythisenzymeweusedasyntheticpartiallysingle-
stranded suicide DNA substrate containing a preferred
type IB TopoI cleavage sequence. This substrate, that was
originally developed to investigate cleavage by hTopoI, acts
as a mechanism-based inactivator of nuclear type IB Topos
by allowing DNA cleavage, while the subsequent religation
reaction is prevented due to diﬀusion of the generated 5 -
OH end (see Figure 2(a)). Prevention of religation, however,
is only conditional and this step of catalysis can be initiated
by the addition of a surplus of a 5 -OH-containing ligator
strand with a sequence matching the protruding noncleaved
strand of the generated cleavage complexes (Figure 2(a)).
First, the ability of pfTopoI with cleave the suicide
DNA substrate was tested in comparison to cleavage by
hTopoI. The two enzymes were incubated with substrate
radiolabeled at the 5 -end of the cleaved strand (to allow
visualization of the cleavage products), the products were
ethanol precipitated, trypsinated, and separated on a dena-
turing polyacrylamide gel prior to visualization by Phospho-
rImaging. As evident from Figure 2(b), pfTopoI cleaved the
substrate and gave rise to cleavage products (marked Cl1
and Cl2) with approximately the same gel electrophoretic
mobilities as those of cleavage products generated by hTopoI
(compare lanes 1 and 2). These products were retained in
the slot of the gel if trypsin digestion was omitted (data
not shown), conﬁrming their identity as covalent pfTopoI-
DNA or hTopoI-DNA complexes. As previously reported in
[54], even after trypsin digestion, the cleavage products of
both pfTopoI and hTopoI were retarded in the gel due to the
covalent attachment of short protease-resistant peptides to
the radiolabeled strand of the DNA substrate. For hTopoI,
the major cleavageproductCl1was previouslydemonstrated
to result from cleavage at the preferred site (indicated by an
arrow in Figure 2(a)), while the minor Cl2 product arises
from cleavage two nucleotides upstream to the cleavage site
[54]. The gel electrophoretic mobility of cleavage products
generated by pfTopoI suggests that this enzyme cleaves the
utilized substrate at the same positions as does hTopoI.
To test the eﬀect of peptide WRWYCRCK on pfTopoI
mediated cleavage, increasing concentrations of the peptide
were incubated with the above-described suicide DNA
substrate prior to addition of pfTopoI. The reactions were
performed essentially as described above and the percentage
of substrate converted to cleavage product shown as a
function of peptide concentration (Figure 2(c)). As previ-
ously reported for vvTopoI and λ-Int, peptide WRWYCRCK
inhibited DNA cleavage by pfTopoI in a dose-dependent
manner, although the observed cleavage inhibition was less
potent than that observed for DNA relaxation.
Using the suicide substrate system, the eﬀect of pep-
tide WRWYCRCK on pfTopoI-mediated religation was
investigated. In this experiment, preformed cleavage com-
plexes were incubated with increasing concentrations of
WRWYCRCK prior to addition of the ligator strand shown
in Figure 2(a). Consistent with previous results obtained
for vvTopoI and λ-Int the peptide did not aﬀect ligation by
pfTopoI (Figure 2(d)).
3.3. Peptide Speciﬁcity. The three peptides tested for activity
against pfTopoI in the present study were previously demon-
strated to inhibit vvTopoI and λ-Int activity with IC50’s
of 0.015–2.3μM, while more unrelated enzyme activities
such as E. coli type IA Topo and restriction endonucleases
were hardly aﬀected by any of the peptides. Although far
from being species-speciﬁc, the peptide inhibitors appear
rather sensitive to even subtle structural diﬀerences between
the diﬀerent target enzymes. This is evident from the
diﬀerent inhibition pattern of pfTopoI observed here (only
WRWYCRCK inhibits pfTopoI) relative to that of the above
mentioned TopoIB type enzymes (inhibited by WYCRCK,
KCCRCK, and WRWYCRCK) [40]. To further address the
speciﬁcity of the pfTopoI active inhibitor WRWYCRCK,
we tested the eﬀect of this peptide on the two restriction
endonucleasesEcoRIandPvuII.Increasing concentrationsofMolecular Biology International 7
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Figure 4: Docking of peptides into the noncovalent pfTopoI-DNA complex. Side view of the ternary pfTopoI-DNA-peptide complex. The
structure represents the best complex obtained from the docking experiment. The protein is shown in red cartoon, the DNA in grey ribbon
and the peptide in licorice, with the atoms coloured with the following code: carbon: cyan, nitrogen: blue, oxygen: red, sulphur: yellow. (a)
Octapeptide WRWYCRCR, (b) hexapeptide WYCRCR, and (c) hexapeptide KCCRCR.
the peptide were incubated with the test plasmid (pUC19)
before addition of either of the restriction enzymes. As
evident from Figure 3, and consistent with previously
published results [40], the peptide had no or only very
modest eﬀect on the cleavage activity of these enzymes,
conﬁrming the speciﬁc action of WRWYCRCK.
All three peptides, WYCRCK, KCCRCK, and
WRWYCRCK have previously been shown to possess an
unspeciﬁc DNA binding capacity, which was conﬁrmed in
the present study (data not shown) [40]. However, the lack
of inhibition of endonuclease activity and the inhibition of
pfTopoI activity only by WRWYCRCK and not by WYCRCK
and KCCRCK even at very high concentrations argues
against peptide inhibition being the result of a simple
competition for noncovalent DNA binding. Indeed, for
vvTopoI and λ-Int, all peptides were demonstrated not to
aﬀect noncovalent DNA interaction and it was suggested
that inhibition was a result of the peptides preventing
the transition from noncovalent to covalent binding, that
is, DNA cleavage, by interfering with the enzyme-DNA
interphase [40].
3.4. Prediction of the Interaction Mode between the Peptide
and the pfTopoI-DNA Complex. Docking experiments have
been carried out to identify the preferential binding site of
the WRWYCRCK octapeptide on the noncovalent pfTopoI-
DNA complex. 250 docking runs were done and the best
complex, having a free energy value of −14.0Kcal/mol, was
selected and analyzed. This complex shows that the peptide
is located in the minor groove cavity in front of the active
site (see Figure 4(a)), establishing many contacts with both
the protein and the DNA bases, as reported in Table 1.
Concerning the DNA contacts, interesting interactions occur
between the peptide and Gua12-Ade15 and Thy32-Thy34
on the scissile and intact strand, respectively. The optimal
positioning of the octapeptide in the minor groove is
due either to a good geometrical ﬁtting between the two
molecules,ortothehigh numberofelectrostaticinteractions
between the positively charged residues of the peptide and
the negatively charged DNA phosphates. As far as the
protein is concerned, interesting interactions occur between
Trp3 and Cys5 of the peptide and Arg310 of pfTopoI and
between Tyr4 and Asp513 of pfTopoI (see Table 1). Residues
Arg310 and Asp513 of the Plasmodium protein correspond
to residues Arg364 and Asp533 of the human enzyme, which
are known from the 3D structure of the ternary drug-DNA-
enzyme complex to directly interact with the camptothecin
drug [55, 56]. The peptide then, positioned in the minor
groove of the DNA just in front of the protein active site,
exerts an inhibition of the cleavage process thus providing
an explanation for the experimental results reported in
Figure 2(c).
An identical docking experiment has been performed
also for the two hexapeptides WYCRCK and KCCRCK, not
having any inhibitory eﬀect on pfTopoI relaxation. The best
docked complexes, having a free energy value of −11.36
and −11.04Kcal/mol, are reported in Figures 4(b) and 4(c)
for the WYCRCK and KCCRCK peptide, respectively. Both
peptides are found in a region diﬀerent from the one found
for the octapeptide. The two hexapeptides are located in
proximity of the major groove in a region far from the
enzyme active site and, in contrast to what was observed for
theoctapeptide,theyarenotabletointeractwithArg310and
Asp513, providing a structural explanation for their lack of
inhibition.
4.Discussion
During recent years, bioactive peptides have been suggested
as an alternative or complement to traditional small-
molecule drugs in the combat against protozoan parasites
[10, 24, 55, 57, 58]. One of the suggested advantages of
peptide drugs in antiparasite treatment relies on the ease
by which such drugs can be selected or modiﬁed to target
desired biological pathways using nature’s own selection
mechanisms or large throughput in vitro screening and/or8 Molecular Biology International
Table 1: Contacts between the peptide WRWYCRCK, and the noncovalent pfTopoI-DNA complex calculated for the best docked complex.
Peptide Protein DNA
Trp1 — —
Arg2 Lys208, Gly313, Glu314, Ser514 Ade13
Trp3 Tyr205, Lys208, Arg310, Arg312, Gly313 Ade14
Tyr4 Arg312, Gly313, Asp513 Gua12, Ade13, Ade14
Cys5 Tyr205, Arg310, Gly311 Ade14
Arg6 Arg312 Gua12, Ade13, Ade14, Ade15, Thy32, Cyt33
Cys7 Lys322 —
Lys8 — Ade15, Cyt33, Thy34
directed evolution setups. Another advantage relies on the
relatively large interphase between peptide drugs and their
target, possibly facilitating an increased speciﬁcity of peptide
drugs compared to small-molecule drugs [25, 59]. Until
recently, high synthesis costs have hampered the possibilities
of developing peptide-based drugs against various relevant
targets. However, with new synthesis strategies and lowered
monomer costs the interest in developing peptide drugs
has markedly increased [24–27]. One of the very promising
strategies was ﬁrst presented by Nagaraja’s research group,
who had taken advantage of antibodies raised by the natural
immune response of mice injected with the desired target, in
the reported cases, Mycobacteria DNA gyrase or TopoI [28–
30]. As a result diﬀerent antibodies with speciﬁc inhibitory
eﬀects on either target have been identiﬁed. Remarkably,
these antibodies appear extremely speciﬁc and show no
activity against the E. coli counterparts of the Mycobacteria
topoisomerases. Hence, these antibodies hold great promise
for the further developmentof Mycobacteria-speciﬁc peptide
d r u g sb a s e do nt h ea m i n oa c i ds e q u e n c eo ft h ea c t i v ep a r t s
of the antibodies [28]. Indeed, several studies highlight the
feasibility in deriving active peptideswith speciﬁcity retained
from the antibodies from which they originate [31–34].
Another reported strategy was based on selecting pep-
tideswithactivity against theTopoI relatedλ-Int from alarge
library [35]. As a result of this study, a number of peptides
with inhibitory eﬀect on the recombinase were identiﬁed.
Some of these, WYCRCK, KCCRCK, and WRWYCRCK,
also inhibited the relaxation activity of vvTopoI [39, 40].
In the present study, we demonstrate that of these peptides,
WRWYCRCK but not WYCRCK, or KCCRCK inhibits DNA
relaxation mediated by pfTopoI. As previously reported
for the peptide inhibition of λ-Int and vvTopoI, it is
speciﬁcally the cleavage reaction of pfTopoI that is inhibited
by WRWYCRCK, while ligation is largely unaﬀected by
the peptide, possibly due to the peptide being unable to
bind to the covalent pfTopoI-DNA cleavage complexes.
The inhibition on cleavage appears to be dependent on
cysteine bridging since the addition of DTT counteracts the
peptide eﬀect. For λ-Int and vvTopoI it was demonstrated
that although the peptide does bind DNA unspeciﬁcally,
the inhibitory eﬀect of active peptides on DNA cleavage
could not be ascribed to a simple competition preventing
noncovalent DNA interaction of the Topos [40]. Rather
the peptides were suggested to prevent the transition from
noncovalent to covalent binding. Although this was not
addressed experimentally for pfTopoI the inhibition of this
enzyme by only one of the peptides, WRWYCRCK, argues
for a speciﬁc inhibition rather than merely an unspeciﬁc
competition for DNA binding. Note that all three peptides
bind DNA in an unspeciﬁc manner [40].
This notion is further supported by molecular docking
experiments in which the molecular mechanism for the
inhibition exerted by the octapeptide was analyzed. This
analysis allowed us to predict the preferential interaction
interface between the noncovalent pfTopoI-DNA complex
and the peptide itself. This is in agreement with the peptide
being able to prevent the transition from noncovalent to
covalent binding. Hence, the complex with the lowest free
energy, that is, the best complex, is represented by the
peptide inserted in the DNA minor groove, near the active
site (Figure 4), where it impedes the catalytic tyrosine to
produce the nick on the scissile strand, as demonstrated by
the cleavage assay (Figure 2). Indeed, the peptide interacts
with two residues in proximity of the active site, Arg310 and
Asp513,which are theplasmodial counterpartforthehuman
residues Arg364 and Asp533 that in the 3D structure of the
human enzyme are in direct contact with the camptothecin
drug [56]. The peptide is stabilized by numerous contacts to
either the protein or the DNA, conﬁrming that it represents
an eﬃcient inhibitor of the enzyme. Docking of the two
noninhibiting peptides, WYCRCK and KCCRCK, into the
noncovalent pfTopoI-DNA complex revealed that these
peptides were located far from the active site of pfTopoI,
which may explain why they do not inhibit pfTopoI.
Although, until now, no species-speciﬁc peptide
inhibitors of parasitic Topos have been reported, we believe
that the presented studies demonstrate the feasibility of
inhibiting Topos relevant in antiparasite treatment and
that molecular docking may pave the road for the rational
development of species-speciﬁc inhibitors.
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